Now Playing
Opinion|Videos|April 22, 2024
Approved Bispecifics for the Treatment of Relapsed/Refractory Multiple Myeloma (R/R MM)
Author(s)Caitlin Costello, MD, Matthew James Pianko, MD
Experts review how the treatment landscape for relapsed/refractory multiple myeloma shifted with the addition of bispecifics, and the currently approved bispecifics available.
Advertisement
Episodes in this series
Advertisement
Related to this article
C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
2
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
3
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
4
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
5